Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury

Thrombosis and Haemostasis

Volumn 91, Issue 3, 2004, Pages 506-513

  Kuyvenhoven, Johan Ph ^a   Molenaar, I Quintus ^a   Verspaget, Hein W ^a   Veldman, Marietta G ^a   Palareti, Gualtiero ^b   Legnani, Cristina ^b   Moolenburgh, Sanne E ^c   Terpstra, Onno T ^a   Lamers, Cornelis B H W ^a   van Hoek, Bart ^a   Porte, Robert J ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Aprotinin; Ischemia reperfusion injury; Liver transplantation; Matrix metalloproteinases; Plasmin

Indexed keywords

APROTININ; ENZYME PRECURSOR; GELATINASE A; GELATINASE B; PLACEBO; PLASMIN; SERINE PROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; ENZYME RELEASE; FEMALE; HUMAN; LIVER ISCHEMIA; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; ZYMOGRAPHY;

EID: 12144290341     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-05-0272     Document Type: Article

References (39)

1. Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001; 33: 960-70.
2. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001; 86: 324-33.
3. Kuyvenhoven JPh, van Hoek B, Blom E, et al. Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various liver diseases and hepatocellular carcinoma. Thromb Haemost 2003; 89: 718-25.
4. Upadhya AG, Harvey RP, Howard TK, et al. Evidence of a role for matrix metalloproteinases in cold preservation injury of the liver in humans and in the rat. Hepatology 1997; 26: 922-8.
5. Clavien PA. Sinusoidal endothelial cell injury during hepatic preservation and reperfusion. Hepatology 1998; 28: 281-5.
6. Upadhya GA, Strasberg SM. Glutathione, lactobionate, and histidine: Cryptic inhibitors of matrix metalloproteinases contained in University of Wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions. Hepatology 2000; 31: 1115-22.
7. Dzik WH, Arkin CF, Jenkins RL, et al. Fibrinolysis during liver transplantation in humans: Role of tissue- type plasminogen activator. Blood 1988; 71: 1090-5.
8. Legnani C, Palareti G, Rodorigo G, et al. Protease activities, as well as plasminogen activators, contribute to the ΣlYtic" state during orthotopic liver transplantation. Transplantation 1993; 56: 568-72.
9. Porte RJ, Bontempo FA, Knot EA, et al. Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation. Transplantation 1989; 47: 978-84.
10. Porte RJ, Bontempo FA, Knot EA, et al. Tissue-type-plasminogen-activator-associated fibrinolysis in orthotopic liver transplantation. Transplant Proc 1989; 21: 3542.
11. Lijnen HR. Elements of the fibrinolytic system. Ann N Y Acad Sci 2001; 936: 226-36.
12. Parks WC, Mecham RP. Matrix metalloproteinases. San Diego: Academic Press, 1998.
13. Baramova EN, Bajou K, Remacle A, et al. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 1997; 405: 157-62.
14. Lijnen HR, Silence J, Lemmens G, et al. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system. Thromb Haemost 1998; 79: 1171-6.
15. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985; 29: 236-61.
16. Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic Ever transplantation: A multicentre randomised double-blind study. Lancet 2000; 355: 1303-9.
17. Porte RJ. Coagulation and fibrinolysis in orthotopic liver transplantation: Current views and insights. Semin Thromb Hemost 1993; 19: 191-6.
18. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: Risk factors for poor function after orthotopic liver transplantation. Hepatology 1994; 20: 829-38.
19. Klar E, Angelescu M, Zapletal C, et al. Definition of maximum cold ischemia time without reduction of graft quality in clinical liver transplantation. Transplant Proc 1998; 30: 3683-5.
20. Gveric D, Hanemaaijer R, Newcombe J, et al. Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage. Brain 2001; 124: 1978-88.
21. Hanemaaijer R, Visser H, Konttinen YT, et al. A novel and simple immunocapture assay for determination of gelatinase- B (MMP-9) activities in biological fluids: Saliva from patients with Sjogren's syndrome contain increased latent and active gelatinase-B levels. Matrix Biol 1998; 17: 657-65.
22. Sier CF, Casetta G, Verheijen JH, et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: A comparison with clinically used tumor markers. Clin Cancer Res 2000; 6: 2333-40.
23. Capper SJ, Verheijen J, Smith L, et al. Determination of gelatinase-A (MMP-2) activity using a novel immunocapture assay. Ann N Y Acad Sci 1999; 878: 487-90.
24. Sier CF, Kubben FJGM, Ganesh S, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996; 74: 413-17.
25. Molenaar IQ, Legnani C, Groenland THN, et al. Aprotinin in orthotopic liver transplantation: Evidence for a prohemostatic, but not a prothrombotic, effect. Liver Transplant 2001; 7: 896-903.
26. Montaner J, Alvarez-Sabin J, Molina C, et al. Matrix metalloproteinase expression after human cardioembolic stroke: Temporal profile and relation to neurological impairment. Stroke 2001; 32: 1759-66.
27. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368-72.
28. Sopata I, Dancewicz AM. Presence of a gelatin-specific proteinase and its latent form in human leucocytes. Biochim Biophys Acta 1974; 370: 510-23.
29. Opdenakker G, van den Steen PE, Dubois B, et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001; 69: 851-9.
30. Yassen KA, Galley HF, Webster NR. Matrix metalloproteinase-9 concentrations in critically ill patients. Anaesthesia 2001; 56: 729-32.
31. Nakamura T, Ebihara I, Shimada N, et al. Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: Effect of fiber-immobilized polymyxin B treatment. Am J Med Sci 1998; 316: 355-60.
32. Danielsen CC, Wiggers H, Andersen HR. Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J Mol Cell Cardiol 1998; 30: 1431-42.
33. Yano M, Omoto Y, Yamakawa Y, et al. Increased matrix metalloproteinase 9 activity and mRNA expression in lung ischemia-reperfusion injury. J Heart Lung Transplant 2001; 20: 679-86.
34. Cursio R, Mari B, Louis K, et al. Rat liver injury after normothermic ischemia is prevented by a phosphinic matrix metalloproteinases inhibitor. FASEB J 2002; 16: 93-5.
35. Falk V, Soccal PM, Grunenfelder J, et al. Regulation of matrix metalloproteinases and effect of MMP-inhibition in heart transplant related reperfusion injury. Eur J Cardiothorac Surg 2002; 22: 53-8.
36. Boeker KHW, Haberkorn CI, Michels D, et al. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of Ever fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002; 316: 71-81.
37. Murawaki Y, Ikuta Y, Koda M, et al. The proMMP-2 activation rate in patients with chronic viral liver disease. Clin Chim Acta 2002; 324: 99-103.
38. Baricos WH, Cortez SL, el Dahr SS, et al. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 1995; 47: 1039-47.
39. Selzner N, Rudiger H, Graf R, et al. Protective strategies against ischemic injury of the liver. Gastroenterology 2003; 125: 917-36.